ストックスクリーナーアプリを入手
4.87
12.86%
-0.73
前日終値:
$5.60
開ける：
$5.5
24時間の取引高:
1.05M
Relative Volume:
1.09
時価総額：
$202.02M
収益：
$134.48M
当期純損益:
$-38.94M
株価収益率:
-5.108
EPS:
-0.9534
ネットキャッシュフロー:
$-19.34M
1週間 パフォーマンス:
+1.24%
1か月 パフォーマンス:
-2.40%
6か月 パフォーマンス:
-49.27%
1年 パフォーマンス:
-60.74%
1日の値動き範囲:
$4.84
$5.74
1週間の範囲:
$4.84
$5.76
52週間の値動き範囲:
$4.48
$13.22
Rxsight Inc Stock (RXST) Company Profile
Compare RXST vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
4.88 | 232.23M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
96.42 | 166.17B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
326.08 | 125.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.59 | 106.49B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.30 | 67.09B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
94.59 | 54.34B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-30 | 開始されました | William Blair | Mkt Perform |
| 2025-07-15 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | ダウングレード | Jefferies | Buy → Hold |
| 2025-07-09 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-07-09 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-07-09 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | 開始されました | Piper Sandler | Neutral |
| 2025-04-09 | ダウングレード | UBS | Buy → Neutral |
| 2025-04-04 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2025-04-03 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-12-20 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-11 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 開始されました | UBS | Buy |
| 2024-10-29 | 開始されました | Jefferies | Buy |
| 2024-08-20 | 繰り返されました | Needham | Buy |
| 2024-08-06 | 繰り返されました | Needham | Buy |
| 2024-05-07 | 繰り返されました | BTIG Research | Buy |
| 2023-12-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | 開始されました | Stifel | Buy |
| 2023-12-04 | 開始されました | Morgan Stanley | Overweight |
| 2023-04-13 | 開始されました | Oppenheimer | Outperform |
| 2022-12-12 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | 開始されました | Needham | Buy |
すべてを表示
Rxsight Inc (RXST) 最新ニュース
RxSight stock tumbles on reduced 2026 sales guidance By Investing.com - Investing.com Nigeria
Alcon, RxSight Begin Co-Developing Presbyopia-Correcting IOLs - Medical Product Outsourcing
Stifel reiterates Hold on RxSight stock, $8 target on Alcon deal By Investing.com - Investing.com Canada
Alcon spends up to $200m to co-develop customisable cataract lenses with RxSight - Yahoo Finance
RxSight reports preliminary Q2 revenue, revises 2026 guidance - MSN
RxSight (RXST) Reiterated at Hold by Stifel as ALC Collaboration Announced - StreetInsider
Rivian Automotive, Penguin Solutions And 3 Stocks To Watch Heading Into Tuesday - Benzinga
RXST: 2026 revenue guidance lowered, gross margin raised, and next-gen lens pipeline advances - TradingView
Alcon, RxSight Partner to Develop Adjustable Presbyopia-Correcting IOLs - VisionMonday.com
RxSight raises FY26 sales guidance to $140M-$160M - scanx.trade
Alcon (ALC) Partners with RxSight for Innovative Lens Developmen - GuruFocus
RxSight reports Q2 revenue of $32-34M, cuts 2026 sales outlook - Investing.com
Alcon, RxSight partner on adjustable lens technology By Investing.com - Investing.com South Africa
RxSight says Q2 results hit by more widespread competitive trialing - TradingView
RxSight cuts 2026 sales outlook, citing competitive headwinds - StreetInsider
RxSight (NASDAQ: RXST) cuts 2026 sales outlook but lifts margin view - Stock Titan
RxSight sees Q2 sales of $27M as Alcon deal adds revenue - Stock Titan
Join Class Action to Recover Losses From RxSight, Inc. (RXST)Contact Levi & Korsinsky Before September 22, 2025 - The National Law Review
RXSTRxSight Inc Options - Finviz
Did RxSight, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST - The National Law Review
RxSight, Inc.(NasdaqGM: RXST) dropped from Russell 2500 Growth Benchmark - marketscreener.com
RxSight Inc. (RXST) Declines Nearly 5% as Stock Approaches Critical SupportOvervalued Signals - dars.gov.et
RxSight, Inc.(NasdaqGM: RXST) added to Russell Microcap Value Benchmark Index - marketscreener.com
RxSight, Inc.(NasdaqGM: RXST) added to Russell 2000 Value Benchmark - marketscreener.com
RxSight, Inc.(NasdaqGM: RXST) dropped from Russell 2000 Growth Benchmark - marketscreener.com
RxSight, Inc.(NasdaqGM: RXST) dropped from Russell 3000E Growth Benchmark - marketscreener.com
RxSight, Inc.(NasdaqGM: RXST) added to Russell Microcap Index - marketscreener.com
Class Action Alert: Levi & Korsinsky Reminds RxSight, Inc. (RXST) Investors of September 22, 2025 Deadline - The National Law Review
Liquidity Mapping Around (RXST) Price Events - Stock Traders Daily
RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
RXST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
RXST Stockholders Have Opportunity to Lead RxSight, Inc. Class Ac - The National Law Review
RxSight, Inc. (RXST) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of September 22, 2025 Deadline - The National Law Review
Class Action Lawsuit Filed: RxSight, Inc. (RXST)Join by September 22, 2025Contact Levi & Korsinsky - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect - The National Law Review
Lost Money on RxSight, Inc. (RXST)? Contact Levi & Korsinsky Before September 22, 2025 to Join Class Action - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
RXST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Investors Urged to Contact Levi & Korsinsky For Information Before September 22, 2025RxSight, Inc. (RXST) - The National Law Review
RXST Forecast — Price Target — Prediction for 2027 - TradingView
RxSight, Inc. Actuals & Estimates (NASDAQ:RXST) - TradingView
RxSight, Inc. Actuals & Estimates (BOATS:RXST) - TradingView
Rxsight Inc (RXST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RXST SEC FilingsRxsight, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Rxsight Inc (RXST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RxSight (RXST) director receives 37,037 restricted stock units in equity grant - Stock Titan
RxSight (RXST) director awarded 37,037 RSUs in equity compensation grant - Stock Titan
RxSight (RXST) director Shweta Maniar receives 37,037 RSU award - Stock Titan
Tamara Fountain at RxSight (RXST) receives 37,037-share RSU award - Stock Titan
Rxsight Inc (RXST) 財務データ
収益
当期純利益
現金流量
EPS
Rxsight Inc (RXST) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Goldshleger Ilya | See remarks |
Sep 25 '25 |
Option Exercise |
4.27 |
23,445 |
99,998 |
65,691 |
0.66%
0.15%
大文字化:
|
ボリューム (24 時間):